摘要
目的 评价依西美坦联合卵巢抑制剂抑那通在治疗绝经前复发转移乳腺癌患者的临床近期疗效和不良反应。方法 回顾性分析我院22例绝经前晚期乳腺癌患者病例材料。患者均应用依西美坦联合抑那通治疗,2~3个月后行疗效观察。结果 治疗后完全缓解和部分缓解患者共9例,有效率40.9%,无严重的不良反应发生。结论 依西美坦联合卵巢抑制剂治疗绝经前复发转移的乳腺癌患者临床疗效确切,不良反应可耐受,具有临床应用价值的意义。
OBJECTIVE To evaluate the efficacy and prognosis in premenopausal breast cancer women receiv- ing exemestane combined with ovarian inhibitors. METHODS 22 advanced breast cancer patients were treated by exemestane and enantone, clinical effects were analyzed. RESULTS The response rate （CR and PR） was 40. 9% , no severe adverse reactions occurred. CONCLUSION Exemestane combined with ovarian inhibitors in the treatment of premenopausal women with advanced breast cancer has a define clinical effect, as well as adverse reactions can be tolerated, being worthy clinical application.
出处
《海峡药学》
2016年第8期106-108,共3页
Strait Pharmaceutical Journal
关键词
依西美坦
抑那通
绝经前
晚期乳腺
Exemestane
Enantone
Premenopansal
Advanced breast cancer
